oritavancin diphosphate · Melinta Therap · NDA 206334
Orbactiv
Earliest generic entry, as listed
16 Jul 2035
Blocked by patent: US 9649352.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9649352 | product | 16 Jul 2035 |
| US 9682061 | use U-1569 | 26 Apr 2030 |
| US 12514899 | use U-4398 | 29 Aug 2029 |
| US 8420592 | use U-1570 | 29 Aug 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206334 · 001 · RLD | powder, intravenous | EQ 400MG BASE/VIAL | 16 Jul 2035 |